Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nova Mentis Life Sciences Corp
(OP:
NMLSF
)
0.0082
+0.0011 (+15.49%)
Streaming Delayed Price
Updated: 3:06 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Nova Mentis Life Sciences Corp
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...
Via
Benzinga
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
April 20, 2023
The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started <
Via
Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...
Via
Benzinga
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
February 14, 2023
Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a...
Via
Benzinga
Nova Mentis Is Looking To Treat Autism With Psilocybin
April 07, 2022
Nova Mentis Life Science Corp. (OTCQB: NMLSF) and the private college Toronto Institute of Pharmaceutical Technology have signed a ...
Via
Benzinga
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
December 27, 2022
The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a...
Via
Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
December 06, 2022
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and...
Via
Benzinga
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
November 30, 2022
Psychedelics biotechs Nova Mentis Life Science Corp. (OTCQB: NMLSF) and Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Sciences Inc.
Via
Benzinga
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
November 17, 2022
Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science...
Via
Benzinga
Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin
September 30, 2022
Amended Autopsy Confirms Elijah McClain Died From Ketamine Injected By Paramedics Called By Cops
Via
Benzinga
Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn
September 29, 2022
Nova Mentis Life Science Corp. (OTCQB: NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry,...
Via
Benzinga
New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
September 17, 2022
Canadian-based psychedelics company Nova Mentis Life Science Corp.
Via
Benzinga
More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
June 16, 2022
The Canadian biotech company Nova Mentis Life Science Corp. (OTCQB: NMLSF) is filing new provisional patent applications to the U.S.
Via
Benzinga
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
June 08, 2022
The world of psychedelics is getting a crossover with another category in the millennial catalog of trendy investments: NFTs.
Via
Benzinga
Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened
June 07, 2022
Nova Mentis Life Science Corp. (OTCQB: NMLSF), also known as NOVA, a biotech company developing psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, recently...
Via
Benzinga
Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study
February 22, 2022
Psilocybin received yet another confirmation of its beneficial effects in the treatment of major depressive disorder, this time, in the long term. ...
Via
Benzinga
This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism
February 16, 2022
Nova Mentis Life Science Corp (OTCQB: NMLSF) is a biotechnology company focused on psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. The...
Via
Benzinga
Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market
February 08, 2022
Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis
January 27, 2022
The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application to Health Canada
Via
Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
November 08, 2021
Detroit Decriminalizes Psychedelics
Via
Benzinga
Exposures
Product Safety
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
October 26, 2021
The Week In Psychedelics
Via
Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
The Week In Psychedelics
Via
Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
October 13, 2021
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.